Trevi Therapeutics Inc (TRVI) earnings · next report Nov 12, 2026
TRVI earnings call
Call time not announced yet · report Thu, Nov 12
Company investor site: ir.trevitherapeutics.com. IR page from the company's last earnings release (Aug 6, 2026).
Next report
Thu, Nov 12, 2026
After the close · In 8 days
Quarter ended Sep 2026
- EPS consensus
- −$0.13 Range −$0.18 – −$0.1110 analystsYear ago −$0.08
- Revenue consensus
- $0 Range $0 – $09 analysts
EPS estimate trend
- 90 days ago−$0.13
- 60 days ago−$0.13
- 30 days ago−$0.13
- 7 days ago−$0.13
- Now−$0.13
Consensus −3.1% over 90 days. Last 30 days: 0 up, 1 down revisions.
Date and consensus: EODHD earnings calendar and estimates, refreshed every 6 hours. “Confirmed” means the provider lists the report session, which it sets once the company announces; “Estimated” is the provider’s expected date.
Follow TRVI into its report
Save it to a free watchlist (no card). Alerts when the date moves or results land are part of Pro.
Earnings move
- Options price in (Nov 12)
- — No options snapshot for this report yet (taken daily in the 7 days before a report, for stocks with listed options).
- Average move after earnings
- ±1.4% Absolute close-to-close move, 2 reports
Options-implied move: the at-the-money straddle (call + put) on the first expiry after the report, divided by the stock’s close, from EODHD end-of-day option chains. It is what the options market prices as the absolute move to that expiry, not a forecast of direction. Move: close before the news → close after it (before the open: prior close → report-day close; after the close: report-day close → next close), adjusted for splits and dividends, from EODHD end-of-day prices. Reports with an unannounced time are not averaged: both candidate moves are stored instead. Per-report moves, gaps, moves vs SPY and the sector, beat/miss asymmetry and implied vs actual are in Lician Pro below.
Latest result
EPSGAAP
−$0.11
vs −$0.11 est. 0.0%
GAAP diluted EPS, SEC 10-Q
Revenue
—
No revenue consensus stored
EPS actuals are checked against the SEC filing and the company’s earnings press release (8-K EX-99.1). A company that reports only GAAP EPS is graded on its SEC diluted EPS; one that reports adjusted EPS is graded on the provider’s adjusted figure when the release confirms it. A figure that matches neither is shown as unverified, with no beat or miss. Revenue actuals come from the SEC filing of the same quarter where we have it.
Beat / miss history
- Beat EPS in 2 of 4
- Aug 6, 2026In lineEPS −$0.11GAAP vs −$0.11 0.0%Rev — vs —
- May 5, 2026MissEPS −$0.09GAAP vs −$0.07 −28.6%Rev — vs —
- Nov 13, 2025BeatEPS −$0.08GAAP vs −$0.10 +20.0%Rev — vs —
- Aug 7, 2025BeatEPS −$0.09GAAP vs −$0.10 +10.0%Rev — vs —
| Reported | Quarter | EPS est. | EPS actual | Surprise | Revenue est. | Revenue | Surprise |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026 | Jun 2026 | −$0.11 | −$0.11GAAP | 0.0% | — | — | — |
| May 5, 2026 | Mar 2026 | −$0.07 | −$0.09GAAP | −28.6% | — | — | — |
| Nov 13, 2025 | Sep 2025 | −$0.10 | −$0.08GAAP | +20.0% | — | — | — |
| Aug 7, 2025 | Jun 2025 | −$0.10 | −$0.09GAAP | +10.0% | — | — | — |
Earnings documents
No earnings 8-K (item 2.02) is stored for this report yet. All TRVI filings: SEC filings.
Documents link to SEC EDGAR. Lician does not publish earnings-call transcripts.
Healthcare peers with similar quant ratings
TRVI is rated 1.87 of 5 among 532 rated Healthcare stocks (Lician quant rating, Nov 4, 2026). How the rating works
- ELVN earnings1.90 · Sell · stock
- ZNTL earnings1.89 · Sell · stock
- CBIO earnings1.88 · Sell · stock
- CDXS earnings1.88 · Sell · stock
- QDEL earnings1.86 · Sell · stock
- CTMX earnings1.85 · Sell · stock
- PRME earnings1.85 · Sell · stock
- SIGA earnings1.84 · Sell · stock
| Quarter | Revenue | EPS | YoY |
|---|---|---|---|
| Q2 FY26 | — | −$0.11 | — |
| Q1 FY26 | — | −$0.09 | — |
| Q3 FY25 | — | −$0.08 | — |
| Q2 FY25 | — | −$0.09 | — |
Trevi Therapeutics Inc (TRVI) is a biotechnology company listed on NASDAQ.
No cached income statement for TRVI yet, so there is no earnings base to recap.
When the next TRVI 8-K Item 2.02 lands, this page should move. Until then the SEC archive is the source.
Period-over-period revenue change is not in cache for TRVI. We will not invent a beat or miss.
Not investment advice. Full TRVI research stays on the stock page; the tape stays on the quote page.
TRVI earnings FAQ
When is TRVI's next earnings date?
Trevi Therapeutics Inc (TRVI) is expected to report on Thu, Nov 12, 2026, after the close. The provider lists the session, which it sets once the company announces. Consensus EPS is −$0.13.
When is the TRVI earnings call?
Trevi Therapeutics Inc has not announced the time of its next earnings call in an SEC filing yet. Its investor relations page (ir.trevitherapeutics.com) lists the webcast when it is scheduled.
Did TRVI beat earnings estimates last quarter?
No. On Aug 6, 2026 Trevi Therapeutics Inc (TRVI) reported adjusted EPS of −$0.11 against a −$0.11 consensus (0.0%), in line.
How often does TRVI beat EPS estimates?
Trevi Therapeutics Inc (TRVI) beat the EPS consensus in 3 of its last 8 reported quarters.
Not investment advice.